Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/equillium-cancels-metacrine-buy-citing-strong-financial-position-after-ono-deal
https://www.globenewswire.com//news-release/2022/12/23/2579251/0/en/Metacrine-and-Equillium-Mutually-Agree-to-Terminate-Definitive-Merger-Agreement.html
https://www.globenewswire.com/news-release/2022/05/12/2442445/0/en/Metacrine-Reports-First-Quarter-2022-Results.html
https://www.globenewswire.com/news-release/2022/03/30/2413247/0/en/Metacrine-Reports-Fourth-Quarter-2021-Results.html
https://www.globenewswire.com/news-release/2022/02/24/2391908/0/en/Metacrine-Announces-Executive-Leadership-Changes.html
https://www.fiercebiotech.com/biotech/metacrine-fired-half-its-staff-mainly-researchers-and-ditches-more-work-to-focus-ibd-after
https://www.globenewswire.com/news-release/2021/11/11/2332615/0/en/Metacrine-Reports-Third-Quarter-2021-Results.html
https://www.marketwatch.com/story/metacrine-shares-drop-56-after-results-for-met642-271634911509
https://www.globenewswire.com/news-release/2021/10/21/2318743/0/en/Metacrine-Reports-Interim-Results-for-MET642-Phase-2a-Trial-in-Patients-with-NASH-and-Announces-a-Strategic-Re-Prioritization-of-Its-Clinical-Development-Programs.html